CytoCore Plans to Begin Trials on First-Ever Uterine Cancer Scan for Early Detection.

Inexpensive Test Using the P2X7 Genetic Marker Anticipated Within Two Years

CHICAGO -- CytoCore, Inc. (OTCBB:CYCR) today announced plans to begin trials for a quick, accurate, inexpensive screening test for endometrial and uterine cancers using a specialized computer-guided image recognition microscope system and the new P2X7 genetic marker to identify pre-cancerous cell changes.

Much as the arrival of the Pap smear back in the 1960's launched routine screenings that have profoundly reduced the number of cervical cancer deaths, CytoCore's new InPath System uterine and endometrial cancer scan, with a wholesale price expected to be $100, will for the first time enable women at risk for uterine cancers and pre-cancers detected in their earliest stages.

The fourth leading cancer among women, some 41,200 cases of uterine cancer will be reported in the United States this year, as compared with about 9,700 cases of cervical cancer, according to the American Cancer Society.

"Some 40 percent of American women between the ages of 35 and 70 exhibit risk factors for endometrial or uterine cancer such as obesity, hypertension, diabetes or family history," said Dr. Steven Waggoner, a nationally recognized gynecological oncologist and member of CytoCore's medical advisory board. "CytoCore's new screening test has a potential target population of between 25 and 28 million women in the United States alone."

Dr. George Gorodeski of University Hospital Case Medical Center in Cleveland (formerly University Hospitals of Cleveland), who is leading CytoCore's effort to bring the early detection test to fruition, sets forth the unusually high degree of accuracy associated with the P2X7 biomarker in an article appearing this month in the American Association for Cancer Research's journal "Cancer Epidemiology Biomarkers & Prevention." (The article may be viewed at: http://cebp.aacrjournals.org/cgi/content/abstract/15/10/1906)

Dr. Gorodeski's study demonstrates that the P2X7 biomarker has a unusually high degree of accuracy for the detection of uterine epithelial cancers, both in terms of sensitivity (where it has scored between 92-100 percent) and specificity (90-100 percent). This combined accuracy is very high relative to the industry standard, which determines any biomarker's combined accuracy above 150 to be clinically useful.

As with cervical cancer, a large number of endometrial and uterine cancers arise from a pre-malignant condition that responds best to early treatment. Currently, uterine cancer is most often diagnosed as a result of abnormal bleeding - which generally occurs after the opportunity for early identification has already been lost.

CytoCore's new test, which Dr. Gorodeski said is about to begin clinical trials at UHCMC and other medical centers, is quick and minimally invasive. A newly designed "endometrial collector" gathers endometrial cells from the uterus with a flushing process that rinses and collects a saline solution through a thin catheter introduced into the uterus. The collected cells are then placed in a preservative solution and sent to a lab, where they are tested for the expression of two markers, including the definitive P2X7 biomarker.

CytoCore's AIPS (Automated Image Proteomic System), a computer guided image recognition microscope system, uses fluorescence to tag and locate any positive cells out of the thousands screened in a typical lab sample. The company has applied for a patent request for its Endometrial Cancer Scan process, which includes the biomarker and the flushing method for cell collection.

Currently some 50 million American women and 100 million women elsewhere around the world have Pap tests done each year at a cost that ranges from $70-$350 per test.

CytoCore estimates that its Endometrial Cancer Scan, whose Phase I trial should be complete within the next six months, has a U.S. market potential in excess of $2 billion revenue annually. Completion of Phase II trials and FDA approval are expected within 24 months.

"This is an exciting project with a strong scientific foundation and important clinical prospects for success," Dr. Gorodeski said. "The biomarker has been tested in a preliminary study of more than 100 patient samples and has consistently produced exciting results. This testing method, if successfully validated, could help care-givers reduce the prevalence of invasive uterine cancer and save the lives of many, many women."

For further information, visit www.CytoCoreInc.com

About CytoCore Inc.

CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com

Dr. Gorodeski has a significant financial interest in this research consisting of equity and salary as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore could generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland, and for CASE University.

Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.